The estimated Net Worth of Thomas R Baruch is at least $2.89 millió dollars as of 12 June 2020. Mr. Baruch owns over 4,947 units of Codexis stock worth over $90,344 and over the last 15 years he sold CDXS stock worth over $2,645,738. In addition, he makes $154,989 as Independent Director at Codexis.
Sign up
Mr. Baruch CDXS stock SEC Form 4 insiders trading
Thomas has made over 9 trades of the Codexis stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 4,947 units of CDXS stock worth $52,488 on 12 June 2020.
The largest trade he's ever made was exercising 125,000 units of Codexis stock on 28 August 2015 worth over $187,500. On average, Thomas trades about 10,343 units every 60 days since 2010. As of 12 June 2020 he still owns at least 33,093 units of Codexis stock.
You can see the complete history of Mr. Baruch stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Thomas Baruch biography
Thomas R. Baruch serves as Independent Director of the Company. Mr. Baruch brings to our board of directors knowledge of the biotechnology and clean technology industries as well as public company governance experience. Since November 2010, Mr. Baruch has served as president and managing general partner of Baruch Future Ventures, LLC, which currently invests in early stage companies focused on resource scarce and climate sensitive markets. Mr. Baruch co-founded Formation 8 in 2011, a venture capital fund where he currently serves as an Emeritus Partner. Earlier, Mr. Baruch formed CMEA Capital in 1988 with New Enterprise Associates (NEA) and 3M Corp. where Mr. Baruch was responsible for managing seven funds at CMEA and led investments resulting in eighteen IPO’s including Aclara Biosciences, Codexis, CNano Technologies, Flextronics, Inc., Intermolecular, and Symyx Technologies, and eight M&A transactions including Silicon Spice, acquired by Broadcom (BRCM). Earlier in his career, Mr. Baruch worked at Exxon Mobil for twelve years and later founded Microwave Technology, Inc. where he served as CEO for six years. In addition to his service as a director of Codexis, Mr. Baruch currently serves on the board of numerous privately held companies and public service entities. Mr. Baruch was a founding member of President Obama’s National Advisory Council on Innovation and Entrepreneurship, where he advised the U.S. Department of Commerce and the White House. Mr. Baruch is a member of the Executive Committee of the U.S. Council of Competitiveness and a member of the Steering Committee of its Energy, Security, Innovation and Sustainability Initiative and the U.S. Manufacturing Competitiveness Initiative. Mr. Baruch has an Engineering degree from Rensselaer Polytechnic Institute, where he currently serves as a Trustee, and a J.D. degree from Capital University, and is a registered U.S. Patent Attorney.
What is the salary of Thomas Baruch?
As the Independent Director of Codexis, the total compensation of Thomas Baruch at Codexis is $154,989. There are 10 executives at Codexis getting paid more, with John Nicols having the highest compensation of $3,408,030.
How old is Thomas Baruch?
Thomas Baruch is 81, he's been the Independent Director of Codexis since 2016. There are no older and 12 younger executives at Codexis.
What's Thomas Baruch's mailing address?
Thomas's mailing address filed with the SEC is C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY, CA, 94063.
Insiders trading at Codexis
Over the last 15 years, insiders at Codexis have traded over $34,923,852 worth of Codexis stock and bought 399,963 units worth $1,488,111 . The most active insiders traders include Ventures Vii, Llc Vivo Vent..., Ventures Life Sciences 2000... és John J Nicols. On average, Codexis executives and independent directors trade stock every 32 days with the average trade being worth of $153,997. The most recent stock trade was executed by Byron L Dorgan on 15 November 2023, trading 20,000 units of CDXS stock currently worth $42,200.
What does Codexis do?
codexis, inc. is a leading protein engineering company applying innovative technologies to unlock the power of proteins™. our proprietary codeevolver® technology platform enables the rapid development and production of highly optimized proteins, custom-designed for your application. codexis’ revolutionary approach to protein engineering starts with an understanding of the desired performance specifications and optimizes a protein specifically to fit these requirements. you get precisely the protein you need for the job you want it to do. guided by proprietary artificial intelligence software and advanced high-throughput screening systems, codexis is able to efficiently generate and introduce function-driven mutations to rapidly improve a protein for its target application. since 2002, codexis’ in-house biochemists, biologists and bioinformatics experts have worked closely with our clients to advance the technologies for protein optimization and production, enabling breakthrough develop
What does Codexis's logo look like?
Complete history of Mr. Baruch stock trades at Codexis
Codexis executives and stock owners
Codexis executives and other stock owners filed with the SEC include:
-
John Nicols,
President, Chief Executive Officer, Director -
John J. Nicols,
Pres, CEO & Director -
Ross Taylor Jr., M.B.A.,
Sr. VP & CFO -
Ross Taylor,
Chief Financial Officer, Senior Vice President -
Bernard Kelley,
Independent Chairman of the Board -
Byron Dorgan,
Independent Director -
Pam Cheng,
Independent Director -
David Smith,
Independent Director -
Patrick Yang,
Independent Director -
Dennis Wolf,
Independent Director -
Thomas Baruch,
Independent Director -
Jennifer Aaker,
Independent Director -
Karen Frechou-Armijo,
Sr. VP & Head of HR -
Asli Aras Ph.D.,
VP of Corp. Devel. -
Dr. Davinder Singh Brar,
Special Advisor to the Board -
Prof. Gerhard N. Mayr,
Special Advisor to the Board -
Robert Sato M.B.A., Ph.D.,
Sr. VP of Pharmaceutical Devel., Quality & Regulatory -
Dr. Stefan Lutz Ph.D.,
Sr. VP of Research -
Rob Wilson Ph.D.,
Sr. VP & GM of Performance Enzymes -
Dr. Gjalt Huisman Ph.D.,
Sr. VP of Strategic Devel. & GM of Biotherapeutics -
Dr. Karl A. Schoene Ph.D.,
Sr. VP of Devel. & Operations -
Kathleen Sereda Glaub,
Director -
Gordon Sangster,
SVP & Chief Financial Officer -
James Lalonde,
SVP, R&D -
Ventures Vii, Llc Vivo Vent...,
-
Douglas T. Sheehy,
SVP, Gen Counsel and Sec. -
Sriram Ryali,
Chief Financial Officer -
Ventures Fund Vii, L.P.Vivo...,
-
David D O'toole,
SVP & Chief Financial Officer -
Alexander Karsner,
Director -
Matthew Tobin,
SVP, Research & Development -
David L. Anton,
SVP, Research and Development -
Ventures Life Sciences 2000...,
-
James R Sulat,
Director -
Mun Yew Wong,
Director -
Brazil Holding B.V. Shell,
10% owner -
Bruce A Pasternack,
Director -
Robert J Lawson,
SVP and CFO -
Brian Paul Dowd,
Interim CFO -
Inc Maxygen,
10% owner -
Peter M Strumph,
Interim President and CEO -
Joseph J. Sarret,
CBO, President Pharmaceuticals -
Peter Seufer Wasserthal,
SVP, Pharmaceuticals -
Enterprises Llc Royal Dutch...,
-
Alan Shaw,
President and CEO -
Enterprises Llc Equilon,
10% owner -
Participacoes Ltda.Royal Du...,
-
Sciences Investment Fund Pt...,
-
Esther Martinborough,
-
H Stewart Parker,
-
Rahul Singhvi,
-
Alison Moore,
-
Margaret Nell Fitzgerald,
See Remarks -
Stephen George Dilly,
See Remarks -
Kevin Norrett,
Chief Operating Officer